Gameto Raises $33M in Series B Financing

Gameto Raises $33M in Series B Financing

Client News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

On May 29, 2024, Gameto, a biotechnology company dedicated to advancing treatment options in women's health, announced the closing of an oversubscribed $33 million Series B financing round, led by Two Sigma Ventures with RA Capital and participation from existing investors, including Insight Partners, Future Ventures and BOLD Capital Partners. The financing will support the clinical development of Fertilo, Gameto’s novel investigational in vitro maturation (IVM) solution containing engineered ovarian support cells (OSCs) to mature eggs outside of the body.

The WilmerHale team advising Gameto included Adam Freiman, Mark Nylen, Gabriella Stearns and Drew Fosque.

 

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel